Opioids

Jails and Prisons Deploy SwabTek™ to Fight Narcotics Use

Retrieved on: 
Thursday, July 29, 2021

The General Narcotics Test can detect multiple classes of narcotics, enabling the user to screen for a broad spectrum of drugs of abuse.

Key Points: 
  • The General Narcotics Test can detect multiple classes of narcotics, enabling the user to screen for a broad spectrum of drugs of abuse.
  • Like all other kits in the SwabTek portfolio, the General Narcotics Test produces instant results and is designed to test samples collected from any surface or medium.
  • The General Narcotics Test was designed to help combat the troubling rise of drug abuse and overdoses facing the United States' prisons and jails.
  • The SwabTek General Narcotics Test Kit screens for many classes drugs of abuse by targeting narcotic family types, and their analogs and bases.

Pear Therapeutics Announces Publication of Healthcare Resource Utilization Data Analysis Showing Real-World Cost Impact of reSET-O® in Treating Opioid Use Disorder

Retrieved on: 
Wednesday, July 28, 2021

Pear Therapeutics, Inc. , today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).

Key Points: 
  • Pear Therapeutics, Inc. , today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).
  • In recent years, OUD has been responsible for approximately two out of every three deaths related to substance use disorder (SUD)14-16.
  • Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

Retrieved on: 
Monday, July 26, 2021

An accidental opioid overdose can happen to anyone taking opioids, across any community.

Key Points: 
  • An accidental opioid overdose can happen to anyone taking opioids, across any community.
  • We are proud to team up with Dani Schaffer, Darren Waller, and this alliance of national nonprofit organizations to help reverse the silence and lessen the stigma of opioid overdoses, which are often accidental.
  • For more information about Reverse the Silence and how to help stop overdoses, visit ReverseSilence.org .
  • These national nonprofit organizations share a commitment to combat drug abuse and to spare other Americans of the opioid epidemic that has devastated so many communities across the country.

Prevent Opioid Abuse Calls on Congress to Pass the Opioid Patients’ Right to Know Act

Retrieved on: 
Thursday, July 22, 2021

Pointing to the record number of opioid overdoses in the wake of the COVID-19 pandemic, Prevent Opioid Abuse today called on Congress to help put the brakes on further spikes in dependence and addiction throughout the nation by moving expeditiously to pass the Opioid Patients Right to Know Act (H1185).

Key Points: 
  • Pointing to the record number of opioid overdoses in the wake of the COVID-19 pandemic, Prevent Opioid Abuse today called on Congress to help put the brakes on further spikes in dependence and addiction throughout the nation by moving expeditiously to pass the Opioid Patients Right to Know Act (H1185).
  • The Opioid Patients Right to Know Act would create a grant program to incentivize states to require prescribers to discuss the addictive qualities of the drugs with patients and inform them of alternative treatment options before prescribing them for acute pain.
  • The Opioid Patients Right to Know Act provides the incentives needed to persuade every state in the nation to adopt this proven prevention measure.
  • The Opioid Patients Right to Know Act is sponsored by U.S. Representative David Trone (D-MD), along with Reps.

Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial

Retrieved on: 
Friday, July 16, 2021

),(STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124.

Key Points: 
  • ),(STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124.
  • OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl.
  • [2]
    The pivotal trial OX124-002 is a 4-period cross-over, comparative bioavailability study in healthy volunteers, comparing two dose regimens of OX124 to two dose regimens of an injection reference product.
  • The study is intended to be the primary support for the OX124 New Drug Application in the US.

Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

Retrieved on: 
Monday, July 12, 2021

Mr. Ruth brings significant commercial experience to Opiant, including leading the highly successful launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration (FDA) to treat opioid overdose.

Key Points: 
  • Mr. Ruth brings significant commercial experience to Opiant, including leading the highly successful launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration (FDA) to treat opioid overdose.
  • Mr. Ruth will begin his employment with Opiant effective today and report directly to Dr. Roger Crystal, President and CEO.
  • OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

Tetra Bio-Pharma Accelerates REBORN1© Trial

Retrieved on: 
Monday, July 12, 2021

Ethics Committee approves REBORN1 protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF.

Key Points: 
  • Ethics Committee approves REBORN1 protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF.
  • Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1 trial.
  • The REBORN1 trial is a head-to-head phase 2 study against an opioid treatment in the management of short and frequent episodes of incapacitating pain (breakthrough pain) requesting immediate release opioid treatment in patients living with cancer.
  • Tetra is in the business of providing the evidence which would see QIXLEEF become an alternative prescription therapy to opioids".

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Retrieved on: 
Monday, July 12, 2021

CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of the health economic model for OLINVYK (oliceridine) injection in Journal of Comparative Effectiveness Research.

Key Points: 
  • CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of the health economic model for OLINVYK (oliceridine) injection in Journal of Comparative Effectiveness Research.
  • The model estimates the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain.
  • I am pleased to have the health economic model now in the published literature a significant milestone that will continue to support the formulary review process for OLINVYK, said Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena.
  • As previously announced, the model calculates a significant decrease in total cost of care per 1,000 patients associated with OLINVYK, compared to IV morphine.

PreveCeutical Files International Patent Application for its Dynorphin Peptides

Retrieved on: 
Wednesday, July 7, 2021

Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management.
  • The International patent application is to protect the dynorphin peptide research that appears to show the most potential for further development as an alternative therapeutic agent to the current opioids, such as morphine, in the management of pain.
  • PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
  • For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook .

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, July 1, 2021

AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • If you suffered a loss due to AcelRx Therapeutics, Inc.'s misconduct, click here .
  • On February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.